Interview 5 Jun 2017 What Lies Ahead in Biotech for the UK’s Top Academic Entrepreneur? …company, Cambridge Antibody Technology (CAT), would go on to be the biggest success story in UK biotech after its team discovered the blockbuster therapeutic antibody, Humira, and became part of… June 5, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer …Ajinomoto Co.’s proprietary site-specific bioconjugation and stable linker technologies compatible with commonly used antibody isotypes. AJICAP technology includes its “off-the-shelf” feature, allowing any therapeutic antibody at any stage of development… January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 29 May 2017 Meet the Founder of the UK’s Best Biotech that Discovered Humira …Antibody Technology (CAT), would go on to be the biggest success story in UK biotech after it discovered the blockbuster therapeutic antibody, Humira, and became part of AstraZeneca in 2006… May 29, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization Antibody-drug conjugates (ADCs) represent an innovative class of potent anti-cancer agents. They combine the specificity of a monoclonal antibody with the potency of a cytotoxic drug, enabling targeted killing of… September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer …antibody-drug conjugate (ADC) candidate, MI130110, against fibrosarcoma and multiple myeloma. Which means the popular ADC field has managed to attract yet another company into what could be a major breakthrough… December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 26 Mar 2024 Large molecule manufacturing: addressing challenges with strategies for success …the characteristics of the molecule. This panel of offerings covers a broad range of protein modalities that include antibody-based products, such as bispecific antibodies, Fc-Fusion proteins, and antibody fragments, and… March 26, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? …but this time around, for the chronic respiratory illness idiopathic pulmonary fibrosis (IPF). The candidate MTX-463 is a human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in IPF. The… February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2020 Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II …the market such as Humira and Cosentyx, these antibody drugs aren’t well suited to subcutaneous injections because they can’t penetrate subcutaneous tissue well. Affibody’s psoriasis candidate is a protein drug… June 22, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2018 Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors …has dosed the first patient in a Phase I/IIa trial with its solid tumors candidate, BT1718. The study will test the drug’s safety and efficacy in around 120 patients with… February 14, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 28 Jul 2022 How can vaccines keep up with evolving Covid-19 variants? …the spike antigen becomes. This makes the key target of the antibody response more subject to mutations,” said Alexandre Le Vert, executive chairman and co-founder of the French vaccine firm… July 28, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2019 Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets …led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to test its first drug candidate… May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2018 Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls…. November 27, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email